A randomized, open-label, comparative, multi-center trial to evaluate contraceptive efficacy, cycle control, safety and acceptability of a monophasic combined oral contraceptive (COC) containing 2.5 mg nomegestrol acetate (NOMAC) and 1.5 mg estradiol (E2), compared to a monophasic COC containing 3 mg drosperinone (DRSP) and 30 micrograms ethinyl estradiol (EE)

Trial Profile

A randomized, open-label, comparative, multi-center trial to evaluate contraceptive efficacy, cycle control, safety and acceptability of a monophasic combined oral contraceptive (COC) containing 2.5 mg nomegestrol acetate (NOMAC) and 1.5 mg estradiol (E2), compared to a monophasic COC containing 3 mg drosperinone (DRSP) and 30 micrograms ethinyl estradiol (EE)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Estradiol/nomegestrol (Primary) ; Drospirenone/ethinylestradiol
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Acronyms RUMBA
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 20 Dec 2016 Results of pooled analysis of two studies (RUMBA and Samba) published in the Contraception
    • 18 May 2012 Results assessing the effects of treatment on dysmenorrhoea outcomes presented at the 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
    • 27 Oct 2011 Merck added as study sponsor
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top